Cargando…
Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660158/ http://dx.doi.org/10.1186/1745-6215-16-S2-P188 |
| _version_ | 1782402745011011584 |
|---|---|
| author | Hall, Peter Waterhouse, Anna Smith, Isabelle Brown, Julia Gregory, Walter Steger, Guenther Bell, Richard Cameron, David |
| author_facet | Hall, Peter Waterhouse, Anna Smith, Isabelle Brown, Julia Gregory, Walter Steger, Guenther Bell, Richard Cameron, David |
| author_sort | Hall, Peter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4660158 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46601582015-12-02 Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial Hall, Peter Waterhouse, Anna Smith, Isabelle Brown, Julia Gregory, Walter Steger, Guenther Bell, Richard Cameron, David Trials Poster Presentation BioMed Central 2015-11-16 /pmc/articles/PMC4660158/ http://dx.doi.org/10.1186/1745-6215-16-S2-P188 Text en Copyright © 2015 Hall et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Hall, Peter Waterhouse, Anna Smith, Isabelle Brown, Julia Gregory, Walter Steger, Guenther Bell, Richard Cameron, David Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial |
| title | Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial |
| title_full | Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial |
| title_fullStr | Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial |
| title_full_unstemmed | Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial |
| title_short | Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial |
| title_sort | independent endpoint event review for the elimination of reporting bias in an open label phase iii pharmaceutical trial |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660158/ http://dx.doi.org/10.1186/1745-6215-16-S2-P188 |
| work_keys_str_mv | AT hallpeter independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT waterhouseanna independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT smithisabelle independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT brownjulia independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT gregorywalter independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT stegerguenther independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT bellrichard independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial AT camerondavid independentendpointeventreviewfortheeliminationofreportingbiasinanopenlabelphaseiiipharmaceuticaltrial |